A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

United States

Hughes Spalding Children's Hospital, Atlanta, Georgia

Egleston Children's Hospital, Atlanta, Georgia

Emory Children's Center, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Scottish Rite Children's Hospital, Atlanta, Georgia